BI-655066 superior to ustekinumab as a short-term treatment for moderate to severe psoriasis April 2, 2015
IMO-8400 as a potential therapy for psoriasis and other immune-mediated inflammatory diseases April 1, 2015
Positive outcome from European decentralized procedure for approval of Soolantra for rosacea March 30, 2015
Cipher Pharmaceuticals acquires Canadian rights to novel treatment for psoriasis and RA March 25, 2015
RSS